选择性内皮素A受体拮抗剂在慢性肾脏病中的应用优化
本文综述内皮素-1(ET-1)通过ETA和ETB受体在肾脏的作用,指出选择性ETA受体拮抗剂在糖尿病肾病、IgA肾病、局灶节段性肾小球硬化和Alport综合征中具有治疗潜力,但液体潴留尤其是严重CKD患者中的心衰风险限制其应用,联用SGLT2i可能减轻该副作用,高选择性ETA拮抗剂如atrasentan和zibotentan的开发有望优化疗效与安全性。
要点
- 选择性ETA受体拮抗剂在多种肾脏病中显示获益,包括糖尿病肾病和IgA肾病。
- 液体潴留和心衰风险是主要副作用,尤其在严重CKD患者中。
- 联用SGLT2i可能通过利尿作用减轻ETA拮抗剂的液体潴留副作用。
核心结论
- 选择性ETA受体拮抗剂是多种肾脏病的潜在治疗选择,但需管理液体潴留风险,联用SGLT2i和高选择性拮抗剂有望优化临床应用。
研究设计与样本
- 本文为综述,总结ET-1及其受体在肾脏病理生理中的作用及选择性ETA拮抗剂的实验与临床研究证据。
主要发现
- ET-1通过ETA受体引起血管收缩,通过ETB受体引起血管舒张,并在肾脏调节液体电解质平衡和肾小球滤过率。
- 在实验和临床研究中,抑制ETA受体在糖尿病肾病、IgA肾病、局灶节段性肾小球硬化和Alport综合征中显示有益。
- 液体潴留可导致心衰,尤其在严重CKD患者中,联用SGLT2i可能通过利尿作用减轻该副作用。
关键数值与推荐
- 首个ERA sparsentan已可用于IgA肾病患者。
- 高选择性ETA拮抗剂如atrasentan和zibotentan正在开发中。
临床怎么用
- 在IgA肾病等肾脏病中可考虑使用选择性ETA拮抗剂,但需监测液体潴留和心衰风险,尤其严重CKD患者。
- 联用SGLT2i可能减轻ETA拮抗剂相关的液体潴留。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Endothelin-1 (ET-1) is a peptide that is involved in various chronic diseases including cardiovascular and kidney disease. ET-1 can bind to two receptors, endothelin A (ETA) and endothelin B (ETB), which are found in different organs and tissues. When ET-1 binds to the ETA receptor, it causes blood vessels to narrow, while binding of ET-1 to the ETB receptor causes blood vessels to widen. These receptors help regulate fluid and electrolyte balance in the kidneys, as well as the kidney's ability to filter various substances out of the body. Overactivation of ET-1 can occur in people with diabetes or obesity, which can damage the structure and function of the kidney.Studies in mice and humans with kidney disease have shown that blocking the ETA receptor improves kidney health. As a result, medicines that specifically block the ETA receptor, known as endothelin receptor antagonists (ERAs), are a promising option for treating these kidney diseases. The first ERA (sparsentan) is now available for use in patients with immunoglobulin A (IgA) nephropathy, a specific type of kidney disease. It should be noted that ERAs can cause side effects. Fluid retention, which can increase the risk of heart failure, is a side effect that is particularly observed in patients with type 2 diabetes and severe kidney disease. This side effect is less often observed in patients with IgA nephropathy or patients without diabetes.Treatment strategies to optimize safe and effective use of ETA blockers are being developed. Overall, these insights offer hope for better care of patients with kidney disease. ABSTRACT: Endothelin-1 (ET-1) is a 21-amino acid peptide involved in numerous cardiovascular and renal processes. ET-1 can bind to endothelin receptor A (ETA) and endothelin receptor B (ETB), which are found in various organs and tissues. In general, binding of ET-1 to the ETA receptor causes vasoconstriction, whereas activation of the ETB receptor leads to vasodilation. In the kidney, endothelin receptors regulate fluid and electrolyte balance, regional blood flow and glomerular filtration rate. In pathological conditions, ET-1 promotes kidney injury through adverse effects on the endothelial glycocalyx, podocytes and mesangial cells, and stimulating inflammation and fibrosis in the tubules. In experimental and clinical studies, inhibition of the ETA receptor has been shown beneficial in a variety of kidney diseases. These include diabetic kidney disease, immunoglobulin A nephropathy, focal segmental glomerulosclerosis and Alport syndrome. Accordingly, selective ETA endothelin receptor antagonists (ERA) may prove a viable therapeutic option in these diseases. However, clinical application is challenged by the occurrence of fluid retention which can lead to heart failure, in particular in patients with severe CKD. Concomitant use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) may mitigate these adverse effects through their diuretic actions. The development of highly selective ETA antagonists, such as atrasentan and zibotentan, and the opportunities of combining these with SGLT2i, holds promise to optimize efficacy and safety of ERAs in clinical practice.
引用
- Moedt E, Wasehuus VS, Heerspink HJL, et al. Selective endothelin A receptor antagonism in chronic kidney disease: improving clinical application. Nephrol Dial Transplant. 2025. PMID: 39907539. doi:10.1093/ndt/gfae214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。